Passage Bio Inc PBGM01 Interim Clinical Data From Cohorts 1-3 of Imagine-1 Call Transcript
Good morning, and welcome to the Passage Bio Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
At this time, I'd like to turn it over to Stuart Henderson, Vice President of Corporate Development and Investor Relations. Stuart, please proceed.
Thank you, operator, and good morning, everyone. Today, we will review interim results from the global Imagine-1 Phase 1/2 clinical trial with PBGM01 in infantile gangliosidosis. Please refer to the press release issued earlier and the slides that we will be using on today's call on the Investors view section of the Passage Bio website.
Before we begin, I'd like to remind you that our presentation this morning will contain forward-looking statements based on our current expectations and beliefs of future events as of today. These statements are subject to a number of risks and uncertainties, including those risk factors from our latest 10-Q that could cause
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |